Telemedicine and Face-to-face Consultations Diagnostic Accuracy Comparison in Gastrointestinal Infection Patients

Sponsor
Hospital Israelita Albert Einstein (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04803435
Collaborator
(none)
100
2
9.3

Study Details

Study Description

Brief Summary

Acute gastroenterocolitis (GECA) in healthy adults is a frequent cause of looking for medical care in emergency care units and most cases are aimed at etiology viral infection or food toxin, being generally self-limited with good prognosis and only need for treatment with behavioral measures and use of medications for relief symptomatic. Anamnesis is the main resource for the diagnosis and stratification of GECA severity and is infrequent alterations of physical examination and complementary examinations without association with symptoms of alert. Telemedicine has become a resource that allows easier and faster access to medical evaluation, with low cost and rational use of resources. Virtual emergency care is part of Hospital Israelita Albert Einstein (HIAE) institutional routine and there is a large number of consultations whose final diagnosis was GECA. It is not known whether the accuracy of diagnosis of GECA by telemedicine is not inferior to the diagnosis by face-to-face evaluation, considered the Golden pattern. The aim of the study is compare the diagnostic accuracy of GECA by telemedicine with that of face-to-face care. It is a prospective randomized study with a population of adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious). Patients whose screening will be excluded of nursing directed for immediate evaluation in the emergency room and patients with dysfunctions organisms or immunosuppression. Patients who accept and sign the informed consent form will be randomized into 2 groups: A) immediate face-to-face evaluation; B) evaluation initially by telemedicine and sequentially at face-to-face evaluation. In both cases, the ICD diagnostics will be compiled and grouped according to clinical significance and will be the primary outcome of the study. Service time, exams requested, guidelines, prescription and destination will also be analyzed. Patients and doctors who undergoing group B assessment will be blinded to the telemedicine assessment data.

Condition or Disease Intervention/Treatment Phase
  • Other: Telemedicine Consultation
  • Other: Face-to-face Consultation
N/A

Detailed Description

The face-to-face assessment will be carried out by the local UPA medical and assistance team and the assessment by telemedicine by the fixed medical team of the HIAE service responsible for urgency / emergency. Both in face-to-face evaluation, as well as telemedicine, clinical data, final diagnosis, destination, total time of care, guidance and prescription will be computed. In the face-to-face evaluation, complementary exams and medications received in situ were computed. Final diagnoses will receive nomenclature according to the International Statistical Classification of Diseases and Problems Health-Related - ICD 10 (institutional medical record requirement - Cerner) and will be grouped according to equivalence of syndromic diagnosis. The diagnosis of the face-to-face assessment is made according to protocols based on extensive medical literature and approved by the institutional clinical staff, being representative of current medical practice and will be considered the gold standard diagnosis. Patients evaluated by telemedicine will be blinded to the diagnosis, recommended destination, guidelines and prescription performed by the medical team. UPA doctors will be blind to the doctor's assessment telemedicine and telemedicine doctors will not have access to the data obtained in the screening.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Telemedicine Evaluation of Immunocompetent Adult Patients With Symptoms Suggestive of Acute Gastrointestinal Infection Compared With Face-to-face Medical Consultation in an Emergency Department: a Randomized Study of Diagnostic Accuracy
Anticipated Study Start Date :
Feb 20, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Adult patients with acute gastrointestinal infection - telemedicine before face-to-face evaluation

Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have undergone telemedicine consultation before face-to-face evaluation

Other: Telemedicine Consultation
Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.

Other: Face-to-face Consultation
Direct face-to-face evaluation (without telemedicine consultation before).

Active Comparator: Adult patients with acute gastrointestinal infection - only face-to-face evaluation

Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have only face-to-face evaluation

Other: Face-to-face Consultation
Direct face-to-face evaluation (without telemedicine consultation before).

Outcome Measures

Primary Outcome Measures

  1. Accuracy of telemedicine diagnosis of adult patients with symptoms compatible with acute gastrointestinal infection [through study completion, an average of 1 year]

    The patient will be evaluated by telemedicine and / or face-to-face consultation and at the end will receive the diagnosis, which will be assigned the ICD code. At the end, these ICDs will be grouped by the same clinical significance and will be compared between the two consultation methods (telemedicine versus face-to-face consultation).

Secondary Outcome Measures

  1. Time of medical care [through study completion, an average of 1 year]

    Comparison of time (minutes) of medical care between telemedicine and face-to-face consultation.

  2. Rate of indication for complementary exams [through study completion, an average of 1 year]

    Comparison of rate (porcentage) of indication for complementary exams between telemedicine and face-to-face consultation.

  3. Types of requested exams [through study completion, an average of 1 year]

    Comparison of types of requested exams (porcentage) between telemedicine and face-to-face consultation.

  4. Guidelines follow-up [through study completion, an average of 1 year]

    Comparison of guidelines follow-up (porcentage) between telemedicine and face-to-face consultation.

  5. Medical prescription [through study completion, an average of 1 year]

    Comparison of medical prescription after completion of the service between telemedicine and face-to-face consultation.

  6. Proposed destination after completion of the service [through study completion, an average of 1 year]

    Comparison of proposed destination (percentage of discharge or hospitalization) after completion of the service between telemedicine and face-to-face consultation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age> 18 years

  • Symptoms present less than 7 days.

  • Without the use of antibiotics in last 30 days prior to the onset of symptoms.

  • No trips abroad in the last 15 days prior to the onset of symptoms.

  • Presence of more than three episodes of watery diarrhea in the last 24 hours with or without symptoms related to the infection (fever 38oC, chills, sweating, myalgia, vomiting) that motivated / were looking for the Emergency Care Unit

  • Signature of informed consent form

Exclusion Criteria:
  • Return to the Emergency Care Unit due to maintenance or aggravation of the complaint

  • Age> 65 years

  • Diagnosis of chronic gastrointestinal diseases, gastritis with or without gastroesophageal reflux disease, previous diverticulitis, previous abdominal surgery, chronic colitis, inflammatory bowel diseases, food intolerances (gluten, lactose)

  • Previous diagnosis of congestive heart failure, HIV / AIDS, active cancer, type I diabetes mellitus, use of any immunosuppressant

  • Diarrhea chronic

  • Patient with emergency room criteria by the nursing evaluation of the triage.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Hospital Israelita Albert Einstein

Investigators

  • Study Director: Eduardo HS Cordioli, MD, Telemedicine Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospital Israelita Albert Einstein
ClinicalTrials.gov Identifier:
NCT04803435
Other Study ID Numbers:
  • 36793220300000071
First Posted:
Mar 17, 2021
Last Update Posted:
Feb 11, 2022
Last Verified:
Mar 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospital Israelita Albert Einstein
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 11, 2022